Here’s Why Cytori Therapeutics Inc (CYTX) Shares Skyrocketed Today


Cytori Therapeutics Inc (NASDAQ:CYTX) was Wall Street’s bull of the day today with shares that flew 74%.

The cause of all the enthusiastic commotion? Japanese drug giant Takeda Pharmaceutical intends to acquire TiGenix, an advanced biopharmaceutical company developing novel stem cell therapies for serious medical conditions, at an acquisition price of EUR 1.78 per share, representing a transaction value of approximately EUR 520 million on a fully diluted basis. Investors see the acquisition of Tigenix as a positive “interest” signal for the regenerative medicine space and specifically for Cytori which has a similar adipose based product.

On the ratings front, Cytori has been the subject of a number of recent research reports. In a report released today, Maxim analyst Jason Kolbert assigned a Buy rating on CYTX, with a price target of $5.00, which represents a potential upside of 1752% from where the stock is currently trading. On November 10, B.Riley FBR’s Andrew D’silva maintained a Hold rating on the stock and has a price target of $0.50.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Andrew D’silva have a yearly average loss of 4.7% and a return of 11% respectively. Kolbert has a success rate of 39% and is ranked #4622 out of 4752 analysts, while D’silva has a success rate of 52% and is ranked #1316.

Cytori is a late stage cell therapy company. that engages in the developement of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy acts principally by improving blood flow, modulating the immune system and facilitating wound repair.